# US 2026/0308220 A1 · Human interleukin-2 variant or derivative thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0308220 A1
- Document ID: US20260308220A1
- Status: Published application
- Kind: A1
- Application number: 19/706,892
- Filed: 2026-06-12
- Published: 2026-10-08
- Earliest claimed: 2018-12-21
- Assignees: Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.; Shanghai Shengdi Pharmaceutical Co., Ltd.
- Applicants: Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.; Shanghai Shengdi Pharmaceutical Co., Ltd.
- Inventors: Lei CHEN; Qiyue HU; Hu GE; Yuan LIN; Hongwei WANG; Yangchao OU; Xianglin KONG; Cheng LIAO; Lianshan ZHANG
- Web page: https://patentgrep.com/patent/US20260308220A1

## CPC

- C07K 14/55: IL-2
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a human interleukin-2 (IL-2) variant having one or more amino acid mutations or a derivative thereof. The IL-2 variant or derivative thereof has increased stability compared to wild-type IL-2 and improved properties as an immunotherapeutic agent. Also disclosed are an immunoconjugate and a pharmaceutical composition which comprise the human IL-2 variant or derivative thereof, a polynucleotide molecule encoding same, a vector, a host cell and a preparation method therefor, as well as the pharmaceutical uses of the IL-2 variant or derivative thereof and the immunoconjugate or pharmaceutical composition comprising the L-2 variant or derivative thereof.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

An IL-2 variant or a derivative thereof, wherein it comprises a first type of mutation, and the first type of mutation comprises G27C and F78C.

### Claim 22 (depends on 21)

The IL-2 variant or the derivative thereof according to claim 21, wherein the first type of mutation further comprises any one selected from the group consisting of 1) to 6) or the combination thereof:
1) N26Q,
2) N29S,
3) N30S,
4) N71Q,
5) Q11C and L132C, and
6) L70C and P82C.

### Claim 23 (depends on 21)

The IL-2 variant or the derivative thereof according to claim 21, which further comprises a second type of mutation or a third type of mutation, wherein:
the second type of mutation can eliminate or reduce the affinity of the IL-2 variant or the derivative thereof to high-affinity receptor (IL-2Rα/β/γ), but retain the affinity to medium-affinity receptor (IL-2Rβ/γ);
the third type of mutation can reduce the affinity of the IL-2 variant or the derivative thereof to both high-affinity receptor (IL-2Rα/β/γ) and medium-affinity receptor (IL-2Rβ/γ), and the affinity to high-affinity receptor is decreased more than that to medium-affinity receptor;
preferably, the second type of mutation is any one selected from the group consisting of 8) to 11), or any combination of 8) to 10):
8) F42A,
9) Y45A,
10) L72G, and
11) NNYKNPKLTRMLTFKF at positions 29-44 mutated into QSMHIDATL;
the third type of mutation is any one selected from the group consisting of 12) to 14) or the combination thereof:
12) N88R or N88G or N88I or N88D,
13) D20H or D20Y, and
14) Q126L.

### Claim 24 (depends on 23)

The IL-2 variant or the derivative thereof according to claim 23, wherein the IL-2 variant or the derivative thereof comprises mutations as shown in any one of 15) to 50):
15) N26Q/G27C/N30S/F42A/L72G/F78C;
16) N26Q/G27C/F78C;
17) G27C/N30S/F78C;
18) G27C/NNYKNPKLTRMLTFKF at positions 29-44 mutated into QSMHIDATL/F78C;
19) G27C/F42A/Y45A/F78C;
20) G27C/F42A/L72G/F78C;
21) G27C/Y45A/L72G/F78C;
22) G27C/F42A/Y45A/L72G/F78C;
23) G27C/N29S/F42A/L72G/F78C;
24) N26Q/G27C/N30S/F78C;
25) N26Q/N29S/G27C/F78C;
26) G27C/N29S/N30S/F78C;
27) G27C/N29S/F78C/F42A/Y45A;
28) G27C/N29S/F78C/F42A/L72G;
29) G27C/N29S/F78C/Y45A/L72G;
30) G27C/N29S/F78C/F42A/Y45A/L72G;
31) G27C/N29S/F78C;
32) G27C/N71Q/F78C;
33) N26Q/G27C/N30S/F42A/N71Q/L72G/F78C;
34) N26Q/G27C/N71Q/F78C;
35) G27C/N30S/N71Q/F78C;
36) G27C/NNYKNPKLTRMLTFKF at positions 29-44 mutated into QSMHIDATL/N71Q/F78C;
37) G27C/F42A/Y45A/N71Q/F78C;
38) G27C/F42A/N71Q/L72G/F78C;
39) G27C/Y45A/N71Q/L72G/F78C;
40) G27C/F42A/Y45A/N71Q/L72G/F78C;
41) G27C/N29S/F42A/N71Q/L72G/F78C;
42) N26Q/G27C/N30S/N71Q/F78C;
43) N26Q/N29S/G27C/N71Q/F78C;
44) G27C/N29S/N30S/N71Q/F78C;
45) G27C/N29S/F78C/F42A/Y45A/N71Q;
46) G27C/N29S/F78C/F42A/N71Q/L72G;
47) G27C/N29S/F78C/Y45A/N71Q/L72G;
48) G27C/N29S/F78C/F42A/Y45A/N71Q/L72G;
49) G27C/N29S/N71Q/F78C; and
50) N30S/N88R/G27C/F78C.

### Claim 25 (depends on 21)

The IL-2 variant or the derivative thereof according to claim 21, wherein the stability of the IL-2 variant or the derivative thereof is increased when compared to the stability of wild type IL-2.

### Claim 26 (depends on 21)

The IL-2 variant or the derivative thereof according to claim 21, which further comprises an amino acid mutation of C125A.

### Claim 27 (depends on 21)

The IL-2 variant or the derivative thereof according to claim 21, wherein the mutation(s) thereof is (are) relative to a wild type IL-2, the amino acid sequence of which is as shown in SEQ ID NO.2, and the numbering of the mutation position is counted from the amino acid A at the second position according to the amino acid sequence shown in SEQ ID NO.2.

### Claim 28 (depends on 21)

The IL-2 variant or the derivative thereof according to claim 21, which comprises amino acids as shown in SEQ ID NO. 12 or SEQ ID NO.28.

### Claim 29 (depends on 21)

The IL-2 variant or the derivative thereof according to claim 21, which is monomeric, and/or PEGylated, and/or glycosylated, and/or albumin-conjugated or albumin-fused, and/or FC-fused, and/or hydroxyethylated, and/or absence of O-glycosylation;
preferably, PEG is linked to the N-terminus of the IL-2 variant;
more preferably, the molecular weight of PEG is 5 KD to 50 KD;
most preferably, the molecular weight of PEG is 20 KD.

### Claim 30 (depends on 21)

A conjugate, comprising the IL-2 variant or the derivative thereof according to claim 21, wherein the IL-2 variant or the derivative thereof is directly linked to a non-IL-2 module or indirectly linked to a non-IL-2 module through a linker;
preferably, the non-IL-2 module is an antigen-binding module;
more preferably, the antigen-binding module is an antibody or antigen-binding fragment thereof;
furthermore preferably, the antibody or antigen-binding fragment thereof targets an antigen present on tumor cells or in an environment of tumor cells;
most preferably, the antibody or antigen-binding fragment thereof is selected from: a polypeptide complex comprising an antibody heavy chain variable region and an antibody light chain variable region, Fab, Fv, sFv, F(ab′) 2, linear antibody, single chain antibody, scFv, sdAb, sdFv, nanobody, peptide antibody peptibody, domain antibody and multispecific antibody.

### Claim 31 (depends on 21)

A pharmaceutical composition, comprising the IL-2 variant or the derivative thereof according to claim 21; wherein the pharmaceutical composition comprises pharmaceutically acceptable diluent(s), carrier(s) or adjuvant(s).

### Claim 32 (depends on 21)

A nucleic acid molecule, encoding the IL-2 variant or the derivative thereof according to claim 21,
preferably, the nucleic acid molecule comprises a polynucleotide as shown in SEQ ID NO.11 or SEQ ID NO.27.

### Claim 33 (depends on 32)

An expression vector, comprising the nucleic acid molecule of claim 32.

### Claim 34 (depends on 33)

A host cell, which comprises the expression vector of claim 33, preferably, the host cell is a prokaryotic or a eukaryotic cell;
more preferably, the host cell is a bacterium or a yeast or a mammalian cell;
most preferably, the host cell is Saccharomyces cerevisiae or Escherichia coli.

### Claim 35 (depends on 21)

A method for treating a proliferative disease, a metastatic proliferative disease or an immune disease, or regulating T cell-mediated immune response, stimulating the immune system of an individual, which comprises administering a therapeutically effective amount of the IL-2 variant or the derivative thereof according to claim 21 to a subject,
preferably, the proliferative disease is tumor or cancer, and the immune disease is diabetes;
more preferably, the tumor or cancer is selected from the group consisting of epithelial cell carcinoma, endothelial cell carcinoma, squamous cell carcinoma, cancer caused by papilloma virus, adenocarcinoma, carcinoma, melanoma, sarcoma, teratocarcinoma, lung tumor, metastatic lung cancer, lymphoma and metastatic renal cell carcinoma.

### Claim 36 (depends on 21)

A method for treating and/or preventing autoimmune disease or autoimmune response due to organ transplantation, the method comprises administering a therapeutically effective amount of the IL-2 variant or the derivative thereof according to claim 21 to a subject,
preferably, the autoimmune disease is selected from the group consisting of type I diabetes, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), eczema, and asthma.

### Claim 37

A method for increasing the stability of IL-2 or derivative or conjugate thereof, the method comprising introducing mutation(s) into the IL-2 or the derivative or the conjugate thereof, wherein said mutation(s) comprises G27C and F78C.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the mutation(s) further comprises any one selected from the group consisting of 1) to 6) or the combination thereof:
1) N26Q,
2) N29S,
3) N30S,
4) N71Q,
5) Q11C and L132C, and
6) L70C and P82C.
